Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Rhythm Pharmaceuticals (RYTM) Misses Q1 EPS by 8c
May 3, 2019 8:38 AM EDTRhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76).
Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-impact loss-of-function (LOF) variantsAnnounced strategy for further development in HET obesity with patients stratified into cohorts based on LOF variantTopline data from pivotal... More